IgA Vasculitis in the Setting of Biologic Therapy for Psoriasis and Recurrent Cutaneous Methicillin-Resistant-Staphylococcus aureus Colonization

Peter A. Young, Michael W. Su, Megan S. Inkeles, Maija Kiuru, Maxwell A. Fung, Wen En Kuo

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

IgA vasculitis is a form of cutaneous small-vessel leukocytoclastic vasculitis (LCV) that has various triggers, including anti-tumor necrosis factor (TNF) α therapy. As the use of more targeted biologic therapies such as the IL-17 inhibitor secukinumab increases, so do reports of associated adverse events. Herein, we describe an uncommon case of IgA vasculitis in a man undergoing biologic therapy with adalimumab and secukinumab for psoriasis with recurrent cutaneous methicillin-resistant Staphylococcus aureus (MRSA) colonization. A review of the current literature also is provided.

Original languageEnglish
Pages (from-to)E4-E10
JournalCutis
Volume110
Issue number4
DOIs
StatePublished - Oct 2022
Externally publishedYes

Fingerprint

Dive into the research topics of 'IgA Vasculitis in the Setting of Biologic Therapy for Psoriasis and Recurrent Cutaneous Methicillin-Resistant-Staphylococcus aureus Colonization'. Together they form a unique fingerprint.

Cite this